Skip to content

Enhancing SUV Accuracy of PET/MR for Clinical Trial Qualification

Enhancing SUV Accuracy of PET/MR for Clinical Trial Qualification

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03603925
Enrollment
37
Registered
2018-07-27
Start date
2019-06-17
Completion date
2021-04-07
Last updated
2021-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Positron Emission Tomography-Magnetic Resonance (PET-MR)

Keywords

Computed tomography, standardized update values

Brief summary

Standardized Uptake Values (SUVs), normalized activity concentration, measured using PET/MR have inaccuracies ≥ 20% which exceeds National Cancer Institute / American College of Radiology Imaging Network (NCI/ACRIN), Radiological Society of North America / Quantitative Imaging Biomarkers Alliance (RSNA/QIBA) specifications and disqualifies PET/MR from multicenter or cooperative group clinical trials. High inaccuracy is primarily due to poor attenuation correction (AC) owing to lack of computed tomography (CT) data. This study will develop acquisition and analyses methods to synthesize CT images from MR data that can be used to achieve SUVs that are within 5% of those obtained using PET/CT (reference standard), thus meeting accuracy requirements needed to qualify for multicenter trials. The overall goal of this research project is to validate clinically practical methods for producing MR-based attenuation correction information which is needed to produce quantitatively accurate PET images from a PET/MR scanner. Existing commercial PET/MR systems use methods that are inaccurate.

Detailed description

Objective The primary objective is to demonstrate that, using the new acquisition and analysis methods for MR-AC, PET SUVs in lesions and normal tissues can be measured using PET/MR and be within 5% agreement of those measured using PET/CT. The secondary objective is to demonstrate visual and quantitative agreement between synthesized CT images generated from MR data and the reference, measured CT images. Study Design This study would like to enroll patients receiving a clinically indicated PET/CT scan. The patients will be asked to agree to a receive research PET/MR scan within the study which requires additional time and potential MR risks for the patient. It does not entail extra injections or radiation exposure. Research acquisition and processing will be performed on the PET/MR data to create PET images that are expected to have quantitatively accurate SUVs. These will be compared to SUVs from the clinical PET/CT which will serve as the reference standard. Outcome By bringing together cutting-edge advances in both MR acquisition and image analyses, the successful completion of these aims will achieve SUVs that are within 5% of those obtained with PET/CT (reference standard) with clinically appropriate acquisition time, image quality, and diagnostic accuracy, so that PET/MR systems meet SUV accuracy requirements needed to qualify for cooperative group clinical trials.

Interventions

DIAGNOSTIC_TESTPositron Emission Test / Magnetic Resonance (PET/MR)

The Philips Ingenuity PET/MR is used for research scanning. Patients receiving a clinically indicated PET/CT, will be approached to be included in this study. There is no special preparation other than that needed for the prerequisite PET/CT scanning. At the completion of the PET/CT scanning, the subject will be taken to the PET/MR scanner, which is in close in proximity, for research scanning. The research scanning would take up to one hour or as tolerated.

DIAGNOSTIC_TESTPositron Emission Test / Computed Tomography (PET/CT)

Patients will receive PET / CT imaging for the detection of cancer or other clinically indicated anomalies. The completed study visit is expected to take approximately 2 hours and not longer than 3 hours.

Sponsors

National Cancer Institute (NCI)
CollaboratorNIH
Case Comprehensive Cancer Center
Lead SponsorOTHER

Study design

Observational model
CASE_CROSSOVER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Receiving PET/CT at University Hospitals Cleveland Medical Center (UHCMC) for a clinical indication * No Contraindications to undergo MR as assessed using University Hospitals (UH) Radiology standard MR assessment form * Has the ability to understand and willingness to sign a written informed consent * The circumference of the volunteer in the body section, as determined using a measuring tape, to be scanned must be less than or equal to 110 cm to avoid field of view limitations on the PET/MR

Exclusion criteria

* Patient size or circumference greater than the MR gantry of the PET/MR. * Pregnancy or lactation. * Contraindications to undergo MR as assessed using UH Radiology standard MR assessment form. * Claustrophobia or inability to tolerate MR examination (lay still for approximately 1 hour and hold breath intermittently). * Individuals who are not willing or capable of giving informed consent or assent (with legal guardian consent).

Design outcomes

Primary

MeasureTime frameDescription
Quantitative agreement between measured CT and CT synthesized from MR data (Hounsfield Units)Up to 3 hours after beginning scanDemonstrate quantitative agreement between measured CT and CT synthesized from MR data
Quantitative agreement in the derived linear attenuation coefficients at 511 kilo electro volts (keV).Up to 3 hours after beginning scanDemonstrate quantitative agreement in the derived linear attenuation coefficients at 511 keV.

Secondary

MeasureTime frameDescription
Percent difference in Standardized Uptake Values (SUVs) in PET/CT scans compared to PET/MR scansUp to 3 hours after beginning scanDemonstrate that SUVs in lesions and normal tissues measured using MR-based attenuation correction (MR-AC) are within 5% of those measured using PET/CT.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026